| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Pain Management, CYP450 3A5 Genotype, Qualitative : 91618
Test CodeCYP35A or 91618
Alias/See Also
CYP3A5 Genotype
CPT Codes
81231
Instructions
Lavender (EDTA) or yellow (ACD Solution A or B).
Transport Container
Transport 4 mL whole blood. (Min: 2 mL)
Transport Temperature
Room temperature.
Methodology
Room temperature: 8 days; Refrigerated: 8 days; Frozen: Unacceptable
Setup Schedule
Wednesday
Report Available
9-16 days (From receipt at performing laboratory)
Limitations
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Reference Range
See Laboratory Report.
Clinical Significance
CYP3A4 and CYP3A5 are liver enzymes that are responsible for metabolizing approximatley 50% of small molecule drugs, and their induction often causes unwanted drug-drug interactions and potential toxicities. Variants of CYP3A4/3A5 are associated with significant phenotypic variations that alter the rate of drug metabolism and may cause increased or decreased drug efficacy or adverse drug reactions.
Detecting genetic predisposition to altered CYP3A4/3A5 metabolism may help avoid drug toxicity and can assist the physician with optimizing therapeutic strategies for maximum efficacy and minimal adverse effects.
Detecting genetic predisposition to altered CYP3A4/3A5 metabolism may help avoid drug toxicity and can assist the physician with optimizing therapeutic strategies for maximum efficacy and minimal adverse effects.
Performing Laboratory
Quest Diagnostics
